SCHEMBL4103249

SCHEMBL4103249

COc1ccc(CNCCc2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.74
ALDH1A1 P00352 3/20 0.74
GLA P06280 1/20 0.74
SMN1; SMN2 Q16637 2/20 0.68
POLB P06746 2/20 0.61
ATM Q13315 2/20 0.61
HTR2A P28223 1/20 0.60
GAA P10253 2/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA4 P22748 1/20 0.59
CA9 Q16790 1/20 0.59
ALOX15 P16050 1/20 0.59
MAPT P10636 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
TP53 P04637 1/20 0.59
THRB P10828 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22222297 0.90 KMT2A (0.66) KDM4EALDH1A1GLASMN1; SMN2POLB
SCHEMBL9668420 0.88 ALDH1A1 (0.74) KDM4EALDH1A1GLASMN1; SMN2POLB
SCHEMBL1966824 0.88 KDM4E (0.74) KDM4EALDH1A1GLASMN1; SMN2POLB
SCHEMBL8497095 0.87 ALDH1A1 (0.65) KDM4EALDH1A1GLASMN1; SMN2MEN1
SCHEMBL7279400 0.86 ALDH1A1 (0.72) KDM4EALDH1A1GLASMN1; SMN2MEN1
SCHEMBL10383114 0.86 KDM4E (0.61) KDM4EALDH1A1GLASMN1; SMN2POLB
Hydrochloric Acid SCHEMBL11451398 0.86 KDM4E (0.72) KDM4EALDH1A1GLASMN1; SMN2MEN1
SCHEMBL7435099 0.85 ATM (0.76) KDM4EALDH1A1GLASMN1; SMN2POLB
SCHEMBL3945922 0.84 KDM4E (0.68) KDM4EALDH1A1GLASMN1; SMN2POLB
SCHEMBL9069985 0.84 KDM4E (0.68) KDM4EALDH1A1GLASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221829-A1 3,4-Dihydroisoquinolinium Salt Derivatives HANWHA CHEMICAL CORPORATION (KR) 2009-09-03 US disclosed
WO-2008078871-A1 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVE COMPOSITION HAVING NEMATICIDAL EFFECT ON B. XYLOPHILUS INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2008-07-03 WO disclosed
EP-1896419-A1 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES HANWHA CHEMICAL CORPORATION (KR) 2008-03-12 EP disclosed
WO-2006129978-A1 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES HANWHA CHEMICAL CORPORATION (KR) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221829-A1 3,4-Dihydroisoquinolinium Salt Derivatives KCNQ3, KCNQ1, KCNQ2 KDM4E 1933/4885ALDH1A1 369/4885GLA 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.